A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.
Luspatercept-aamt Approved for Anemia in Adults With MDS
The FDA has approved luspatercept-aamt for the treatment of anemia that requires 2 or more red blood cell transfusions over 8 weeks in adults...
Putting Mutation Testing in Myeloid Malignancies to the Test
In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...
Chk1 Inhibition Shows Efficacy for Splicing Factor Mutant MDS and Leukemia
A new study found Chk1 inhibition with or without splicing modulators may be an effective targeted treatment approach for splicing factor mutant myelodysplastic syndromes...
Luspatercept Reduces Anemia Severity, Improves Rate of Transfusion Independence in MDS
Compared with placebo, treatment with luspatercept improved the 12- to 16-week rate of red blood cell (RBC) transfusion independence in patients with lower-risk myelodysplastic...
FDA Grants Breakthrough Designation to APR-246 for MDS
The FDA granted breakthrough therapy designation to APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) and a TP53...
Patients With SCD and TP53 Mutations May Develop Myeloid Malignancy After Unsuccessful AlloHCT
Population studies have shown that patients with sickle cell disease (SCD) who have undergone an unsuccessful allogeneic hematopoietic cell transplantation (alloHCT) have an increased...
Gilead Acquires Magrolimab Manufacturer Forty Seven, Inc. for $4.9 Billion
In its largest acquisition since purchasing Kite Pharma in 2017, Gilead announced that it has acquired cancer biotech Forty Seven, Inc. for $4.9 billion.
Forty...
A 42-Item Frailty Index Improves Survival Prediction in Myelodysplastic Syndromes
In a recent Leukemia paper, researchers reported on a new 42-variable frailty index (FI) for patients with myelodysplastic syndromes (MDS), which appears to improve...
Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome
In a small study of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...
Perspectives on 2019’s New Hematology Drug Approvals
In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...
